Solid Lipid Nanoparticles for Topical Delivery of Acitretin for the Treatment of Psoriasis by Design of Experiment

DOI:

https://doi.org/10.37285/ijpsn.2019.12.2.5

Authors

  • Rajkumar Aland
  • Ganesan M
  • P. Rajeswara Rao
  • Bhikshapathi D. V. R. N.

Abstract

The main objective for this investigation is to develop and optimize the solid lipid nanoparticles formulation of acitretin for the effective drug delivery. Acitretin loaded SLNs were prepared by hot homogenization followed by the ultrasonication using Taguchi’s orthogonal array with eight parameters that could affect the particle size and entrapment efficiency. Based on the results from the analyses of the responses obtained from Taguchi design, three different independent variables including surfactant concentration (%), lipid to drug ratio (w/w) and sonication time (s) were selected for further investigation using central composite design. The  lipid Dynasan-116, surfactant poloxomer-188 and co surfactant egg lecithin resulted in better percent drug loading and evaluated for particle size, zeta potential, drug entrapment efficiency, in vitro drug release and stability. All parameters were found to be in an acceptable range. TEM analysis has demonstrated the presence of individual nanoparticles in spherical shape and the results were compatible with particle size measurements.  In vitro drug release of optimized SLN formulation (F2) was found to be 95.63 ± 1.52%, whereas pure drug release was 30.12 after 60 min and the major mechanism of drug release follows first order kinetics release data for optimized formulation (F2) with non-Fickian (anomalous) with a strong correlation coefficient (R2 = 0.94572) of Korsemeyer-Peppas model. The total drug content of acitretin gel formulation was found to 99.86 ± 0.012% and the diameter of gel formulation was 6.9 ± 0.021 cm and that of marketed gel was found to be 5.7 ± 0.06 cm, indicating better spreadability of SLN based gel formulation. The viscosity of gel formulation at 5 rpm was found to be 6.1 x 103 ± 0.4 x 103 cp. The release rate (flux) of acitretin across the membrane and excised skin differs significantly, which indicates about the barrier properties of skin. The flux value for SLN based gel formulation (182.754 ± 3.126 μg cm−2 h−1) was found to be higher than that for marketed gel (122.345 ± 4.786 μg cm−2 h−1). The higher flux and Kp values of SLN based gel suggest that it might be able to enter the skin easily as compared with marketed gel with an advantage of low interfacial tension of the emulsifier film that ensures an excellent contact to the skin. This topically oriented SLN based gel formulation could be useful in providing site-specific dermal treatment of psoriasis

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Keywords:

Acitretin, Psoriasis, Taguchi design, SLN, Dynasan-116, Topical gel

Downloads

Published

2020-03-31

How to Cite

1.
Aland R, M G, Rao PR, D. V. R. N. B. Solid Lipid Nanoparticles for Topical Delivery of Acitretin for the Treatment of Psoriasis by Design of Experiment. Scopus Indexed [Internet]. 2020 Mar. 31 [cited 2024 Dec. 26];12(2):4474-91. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/293

Issue

Vol. 12 No. 2 (2019): March-April 2019

Section

Research Articles
Crossref
Scopus
Google Scholar
Europe PMC

References

Allen JG and Bloxham DP (1989). The pharmacology and pharmacokinetics of retinoids. Pharmacol Ther 40: 1–27.
Bachhav YG and Patravale VB (2009). Microemulsion based vaginal gel of fluconazole: Formulation, in vitro and in vivo evaluation. Int J Pharm 365:175-179
Cameron JB and Voohees AS (2014). History of Psoriasis. Springer, London.
Cavalli R, Caputo O and Carlotti ME (1997). Sterilization and freeze drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148: 47-54.
Chiang A, Tudela E and Maibach HI (2012). Percutaneous absorption in diseased skin: an overview. J Appl Toxicol 32: 537-563.
Emami J, Mohiti H, Hamishehkar H and Varshosaz J (2015). Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci 10(1): 17-33.
Feldman SR, Fleischer AB, Jr and Cooper JZ (2000). New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 39(1): 41-4.
Gattu S and Maibach HI (2010). Enhanced absorption through damaged skin: an overview of the in vitro human model. Skin Pharmacol Physiol 23: 171-176.
Griffiths CE and Barker JN (2007). Pathogenesis and clinical features of psoriasis. Lancet 370 (9583): 263-271.
Gupta S, Bansal R, Gupta S, Jindal N, Jindal A (2013). Nanocarriers and nanoparticles for skin care and dermatological treatments. Ind Dermatol online j 4 (4): 267-272.
Horn EJ, Fox KM, Patel V, Chiou CF, Dann F and Lebwohl M (2007). Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 57(6): 957-62.
Hsia E, Johnston MJ, Houlden RJ, Chern WH and Hofland HE (2008). Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. J Invest Dermatol 128: 125-130.
Hu C and Rhodes DG (1999). Proniosomes: a novel drug carrier preparation. Int J Pharm 185(1): 23-35.
Hung CF, Fang CL, Al-Suwayeh SA, Yang SY and Fang JY (2012). Evaluation of drug and sunscreen permeation via skin irradiated with UVA and UVB: comparisons of normal skin and chronologically aged skin. J Dermatol Sci 68: 135-148.
Lee CS and Koo J (2005). A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opi Pharmacother 6: 1725-1734
Levine D and Gottlieb A (2009). Evaluation and management of psoriasis: an internist’s guide. Med Clin North Am 93(6): 1291-303.
Maia CS, Mehnert W and Schafer-Korting M (2000). Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 196:165-7.
Manjunath K and Venkateswarlu V (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Contr Rel 107: 215-28.
Mease P (2006). Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 8(5): 348-54.
Mehrabi D, DiCarlo JB, Soon SL and McCall CO (2002). Advances in the management of psoriasis: monoclonal antibody therapies. Int J Dermatol 41(12): 827-35.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL and Gordon KB (2008). Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58(5): 826-50.
Muller RH, Mader K and Gohla S (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 50: 161-77.
Parisi R, Symmons DP, Griffiths CE and Ashcroft DM (2013). Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2): 377-385.
Perera GK, Di Meglio P and Nestle FO (2012). Psoriasis. Annu Rev Pathol 7: 385-422.
Raychaudhuri SK, Maverakis E and Raychaudhuri SP (2014). Diagnosis and classification of psoriasis. Autoimmun Rev 13 (4-5): 490-495.
Ritu Goyal, Lauren K. Macri, Hilton M. Kaplan, and Joachim Kohn (2016). Nanoparticles and nanofibers for topical drug delivery. J Control Release 240: 77-92.
Ross RJ (1989). Taguchi Techniques for Quality Engineering, McGraw-Hill, NewYork.
Roy A (1990). Primer on the Taguchi Method, Van Nostrand Reinhold, New York.